Salts, crystal forms, and production methods thereof
Andrea Bauer, North Reading, MA (US); Nandkumar Nivritti Bhogle, Shrewsbury, MA (US); Xiaoxia Chen, Acton, MA (US); Shahla Jamzad, Belmont, MA (US); Robert Joseph Prytko, Millbury, MA (US); Kostas Saranteas, Littleton, MA (US); Michael Joseph Sizensky, South Grafton, MA (US); Harold Scott Wilkinson, Westboro, MA (US); and Haitao Zhang, Shrewsbury, MA (US)
Assigned to Sumitomo Pharma America, Inc., Marlborough, MA (US)
Filed by Sumitomo Pharma America, Inc., Marlborough, MA (US)
Filed on Jul. 22, 2022, as Appl. No. 17/814,378.
Application 17/814,378 is a continuation of application No. 17/006,101, filed on Aug. 28, 2020, granted, now 11,440,921.
Application 17/006,101 is a continuation of application No. 16/277,443, filed on Feb. 15, 2019, granted, now 10,815,249, issued on Oct. 27, 2020.
Claims priority of provisional application 62/710,416, filed on Feb. 16, 2018.
Prior Publication US 2022/0402937 A1, Dec. 22, 2022
1. A compound which is crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine hydrochloride characterized by a powder x-ray diffraction pattern comprising peaks, in terms of 2-theta, at 8.6±0.2°, 17.2±0.2°, and 25.9±0.2°.